^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | beta-escin (MAM-06.301) (Immunomodulator, Nitric oxide modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Published date:
09/20/2022
Excerpt:
β-escin administration also significantly retarded tumor growth and angiogenesis in a trastuzumab-resistant JIMT-1 xenograft model via downregulation of CSC-associated markers and intracellular domain HER2….Taken together, our findings highlight β-escin as a promising candidate for the treatment of trastuzumab-resistant HER2-positive breast cancers.
DOI:
10.1186/s12935-022-02713-9
